Outcome prediction by the 2022 European LeukemiaNet genetic-risk classification for adults with acute myeloid leukemia: an Alliance study

Outcome prediction by the 2022 European LeukemiaNet genetic-risk classification for adults with acute myeloid leukemia: an Alliance study

Recently, the European LeukemiaNet (ELN) revised its genetic-risk classification of acute myeloid leukemia (AML). We categorized 1637 adults with AML treated with cytarabine/anthracycline regimens according to the 2022 and 2017 ELN classifications. Compared with the 2017 ELN classification, 2022 fav...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Leukemia 2023-04, Vol.37 (4), p.788-798
Hauptverfasser: Mrózek, Krzysztof, Kohlschmidt, Jessica, Blachly, James S., Nicolet, Deedra, Carroll, Andrew J., Archer, Kellie J., Mims, Alice S., Larkin, Karilyn T., Orwick, Shelley, Oakes, Christopher C., Kolitz, Jonathan E., Powell, Bayard L., Blum, William G., Marcucci, Guido, Baer, Maria R., Uy, Geoffrey L., Stock, Wendy, Byrd, John C., Eisfeld, Ann-Kathrin
Format: Artikel
Sprache:eng
Schlagworte:
14/32
14/63
45/22
45/23
631/208/68
631/67/68
692/420/2489/68
692/499
Abnormalities
Acute myeloid leukemia
Adult
Adults
Anthracycline
Cancer Research
Classification
Critical Care Medicine
Cytarabine
Cytogenetics
fms-Like Tyrosine Kinase 3 - genetics
Hematology
Humans
Intensive
Internal Medicine
Leukemia
Leukemia, Myeloid, Acute - therapy
Medicine
Medicine & Public Health
Mutation
Myelodysplastic syndrome
Nucleophosmin
Oncology
Prognosis
Risk
Risk Factors
Risk groups
Treatment Outcome
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Recently, the European LeukemiaNet (ELN) revised its genetic-risk classification of acute myeloid leukemia (AML). We categorized 1637 adults with AML treated with cytarabine/anthracycline regimens according to the 2022 and 2017 ELN classifications. Compared with the 2017 ELN classification, 2022 favorable group decreased from 40% to 35% and adverse group increased from 37% to 41% of patients. The 2022 genetic-risk groups seemed to accurately reflect treatment outcomes in all patients and patients aged
ISSN:0887-6924
1476-5551
DOI:10.1038/s41375-023-01846-8